drugset / Trial / NCT04430699

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

NCT04430699 ↗

Phase 2 Active not recruiting 24 enrolled Massachusetts General Hospital Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: * Cisplatin (standard of care drug) * Pembrolizumab (investigational drug) * Radiation Therapy (standard of care intervention)

Timeline

Start
2020-07-29
Primary completion
2026-04-30
Completion
2028-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody — Intravenous
Background Cisplatin Other / unclassified — Intravenous